

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	7	4.0	174.0	(69.7-358.5)
Female	1	2.1	nc	(nc-nc)	Female	5	2.9	170.2	(54.8-397.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	21	24.8	84.6	(52.4-129.4)	Female	5	2.9	170.8	(55.1-398.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	5	6.8	73.8	(23.8-172.3)	<b><u>Ovary</u></b>				
Female	4	6.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	27	23.4	115.6	(76.2-168.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.2	119.8	(38.6-279.6)
Male	3	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	7	5.6	124.4	(49.8-256.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	67	84.4	79.4	(61.5-100.8)
Female	1	0.7	nc	(nc-nc)	Female	71	80.3	88.4	(69.1-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	11.6	43.3	(13.9-101.0)					
Female	3	11.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	13.4	134.7	(79.8-212.9)	Male	9	8.5	105.3	(48.0-199.9)
Female	7	5.0	139.9	(56.0-288.3)	Female	12	6.9	174.0	(89.8-303.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	7.6	79.0	(28.8-171.9)
Female	41	56.7	72.3	(51.9-98.1)	Female	14	7.0	199.8	(109.2-335.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	8	6.2	129.6	(55.8-255.4)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	15	14.2	105.5	(59.0-174.1)	<b><u>Ovary</u></b>				
Female	10	14.8	67.4	(32.2-123.9)	Female	4	4.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.6	168.7	(61.6-367.1)	Male	4	4.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	46	45.5	101.1	(74.0-134.8)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.1	nc	(nc-nc)
Male	4	7.3	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	6	4.4	136.2	(49.7-296.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.6	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	9.7	61.9	(22.6-134.7)
Male	3	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.9	nc	(nc-nc)	Female	12	13.1	91.5	(47.2-159.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.6	nc	(nc-nc)	Male	175	175.0	100.0	(85.8-116.0)
Female	2	1.6	nc	(nc-nc)	Female	178	188.1	94.6	(81.2-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	31	24.0	129.3	(87.9-183.6)					
Female	36	26.5	135.6	(95.0-187.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	6.1	131.0	(56.4-258.2)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	21	25.4	82.6	(51.1-126.3)
Female	0	0.2	nc	(nc-nc)	Female	21	20.6	101.8	(63.0-155.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.7	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	14.2	98.8	(54.0-165.8)	Male	2	9.2	nc	(nc-nc)
Female	5	4.1	122.5	(39.5-285.8)	Female	6	6.6	90.6	(33.1-197.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	179.3	(57.8-418.5)	Male	2	2.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	5	1.9	259.9	(83.8-606.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	107.3	(49.0-203.8)
Female	54	52.7	102.4	(76.9-133.6)	Female	5	6.1	81.7	(26.3-190.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.7	nc	(nc-nc)
Male	11	16.1	68.2	(34.0-122.1)	<b><u>Ovary</u></b>				
Female	12	13.1	91.6	(47.3-160.0)	Female	1	4.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	6	5.1	118.2	(43.2-257.4)
Female	0	0.8	nc	(nc-nc)	Female	6	4.1	145.0	(53.0-315.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	27	48.6	55.6	(36.6-80.9)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.4	nc	(nc-nc)
Male	9	8.0	112.2	(51.2-213.0)	Female	0	1.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.6	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	10.4	124.9	(66.4-213.6)
Male	5	5.8	86.5	(27.9-201.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	11	12.0	91.7	(45.7-164.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	140	189.3	74.0	(62.2-87.3)
Female	0	1.4	nc	(nc-nc)	Female	179	169.4	105.7	(90.8-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	20	24.7	81.1	(49.5-125.3)					
Female	31	21.5	144.3	(98.0-204.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	14.4	118.2	(68.8-189.3)	Male	22	8.1	270.6	(169.5-409.7)
Female	10	5.1	196.6	(94.1-361.7)	Female	11	5.4	204.9	(102.2-366.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	5	2.2	229.0	(73.8-534.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.1	70.1	(22.6-163.5)
Female	49	44.4	110.3	(81.6-145.8)	Female	7	6.4	110.1	(44.1-226.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	8	5.3	152.3	(65.6-300.2)
<b><u>Colon / Rectum</u></b>					Female	1	2.6	nc	(nc-nc)
Male	19	13.9	137.2	(82.6-214.2)	<b><u>Ovary</u></b>				
Female	14	14.1	99.3	(54.2-166.5)	Female	3	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	7	4.8	146.7	(58.8-302.3)
Female	0	1.0	nc	(nc-nc)	Female	6	5.1	118.5	(43.3-257.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	48	42.5	112.9	(83.2-149.6)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.2	nc	(nc-nc)
Male	6	6.4	93.1	(34.0-202.7)	Female	1	1.8	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.5	nc	(nc-nc)
Male	8	4.9	161.7	(69.6-318.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.5	nc	(nc-nc)	Female	11	10.5	104.5	(52.1-187.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.2	nc	(nc-nc)	Male	192	167.9	114.4	(98.8-131.7)
Female	1	1.5	nc	(nc-nc)	Female	181	161.5	112.0	(96.3-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	22	25.4	86.7	(54.3-131.3)					
Female	27	26.7	101.0	(66.5-146.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	39.9	117.9	(86.6-156.7)	Male	22	25.5	86.3	(54.1-130.7)
Female	14	13.9	100.6	(55.0-168.9)	Female	25	19.6	127.7	(82.6-188.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	7.5	160.1	(82.6-279.6)	Male	13	8.1	160.9	(85.6-275.2)
Female	7	6.1	115.0	(46.1-236.9)	Female	9	6.3	143.5	(65.5-272.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	26	22.7	114.7	(74.9-168.1)
Female	173	156.5	110.6	(94.7-128.3)	Female	17	19.5	87.3	(50.8-139.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.2	114.6	(41.8-249.4)	Male	20	18.1	110.7	(67.6-171.0)
<b><u>Colon / Rectum</u></b>					Female	8	8.2	97.2	(41.8-191.5)
Male	39	43.0	90.7	(64.5-124.0)	<b><u>Ovary</u></b>				
Female	47	41.6	112.9	(83.0-150.2)	Female	21	13.7	152.8	(94.5-233.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	10.4	67.4	(27.0-138.9)	Male	17	13.9	122.2	(71.2-195.7)
Female	3	2.7	nc	(nc-nc)	Female	16	13.9	114.9	(65.6-186.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	117	128.7	90.9	(75.2-109.0)
Female	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	9.3	nc	(nc-nc)
Male	23	21.4	107.5	(68.1-161.3)	Female	5	5.3	93.7	(30.2-218.6)
Female	9	12.3	72.9	(33.3-138.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.0	100.2	(32.3-233.9)
Male	5	6.0	82.9	(26.7-193.4)	<b><u>Thyroid</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	12	9.6	124.4	(64.2-217.3)
<b><u>Leukemia</u></b>					Female	36	28.2	127.5	(89.3-176.6)
Male	17	15.8	107.8	(62.8-172.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	22	11.2	196.5	(123.1-297.6)	Female	49	35.4	138.3	(102.3-182.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	13.6	73.4	(35.1-134.9)	Male	513	514.5	99.7	(91.3-108.7)
Female	2	4.4	nc	(nc-nc)	Female	599	524.7	114.2	(105.2-123.7)
<b><u>Lung and Bronchus</u></b>									
Male	67	71.1	94.3	(73.1-119.7)					
Female	76	75.0	101.4	(79.9-126.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	23.0	73.8	(43.0-118.2)	Male	8	16.7	47.8	(20.6-94.2)
Female	9	8.4	107.0	(48.8-203.1)	Female	8	14.3	56.0	(24.1-110.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.3	127.7	(55.0-251.6)	Male	3	4.8	nc	(nc-nc)
Female	6	4.8	126.2	(46.1-274.7)	Female	5	3.8	130.5	(42.1-304.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	15.2	118.6	(70.2-187.4)
Female	88	99.8	88.2	(70.7-108.6)	Female	14	12.6	111.5	(60.9-187.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.3	164.0	(65.7-337.9)	Male	6	12.0	50.0	(18.2-108.7)
<b><u>Colon / Rectum</u></b>					Female	9	5.2	171.5	(78.3-325.6)
Male	31	27.1	114.2	(77.6-162.1)	<b><u>Ovary</u></b>				
Female	16	26.5	60.3	(34.5-98.0)	Female	4	9.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.2	96.9	(35.4-210.8)	Male	8	8.3	96.6	(41.6-190.3)
Female	0	1.6	nc	(nc-nc)	Female	18	8.6	210.5	(124.7-332.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	59	78.2	75.5	(57.5-97.4)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	5.7	176.3	(84.4-324.2)
Male	5	14.5	34.5	(11.1-80.5)	Female	3	3.4	nc	(nc-nc)
Female	10	7.9	127.0	(60.8-233.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.8	nc	(nc-nc)
Male	6	3.6	165.5	(60.4-360.3)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	8	8.1	99.2	(42.7-195.5)
<b><u>Leukemia</u></b>					Female	41	24.1	170.4	(122.2-231.1)
Male	14	11.2	124.5	(68.0-208.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.1	123.5	(59.1-227.1)	Female	16	21.6	74.0	(42.3-120.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	8.4	178.9	(100.1-295.1)	Male	320	327.0	97.9	(87.4-109.2)
Female	7	2.7	258.4	(103.5-532.5)	Female	354	341.0	103.8	(93.3-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	56	40.7	137.7	(104.0-178.8)					
Female	58	43.6	133.0	(101.0-171.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.4	137.9	(50.4-300.1)	Male	5	2.7	187.9	(60.6-438.5)
Female	2	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	12	17.0	70.6	(36.4-123.3)	Female	1	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.9	nc	(nc-nc)
Male	6	4.6	129.4	(47.3-281.7)	<b><u>Ovary</u></b>				
Female	3	4.5	nc	(nc-nc)	Female	5	1.5	333.3	(107.4-777.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	19	14.8	128.2	(77.2-200.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.0	124.0	(40.0-289.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	68	55.9	121.7	(94.5-154.3)
Female	0	0.5	nc	(nc-nc)	Female	40	56.4	70.9	(50.7-96.6)
<b><u>Lung and Bronchus</u></b>									
Male	14	7.6	184.5	(100.8-309.6)					
Female	3	8.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	6	1.7	360.4	(131.6-784.4)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.8	102.6	(37.5-223.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	26	20.7	125.6	(82.0-184.1)
Female	0	0.2	nc	(nc-nc)	Female	14	18.5	75.7	(41.4-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.6	nc	(nc-nc)					
Female	4	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	5.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.3	94.6	(30.5-220.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	14	19.0	73.6	(40.2-123.4)
Female	0	0.2	nc	(nc-nc)	Female	10	18.1	55.1	(26.4-101.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.4	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	66	65.7	100.4	(77.7-127.7)	Male	22	40.9	53.8	(33.7-81.4)
Female	14	24.2	57.7	(31.5-96.9)	Female	20	32.4	61.6	(37.6-95.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.0	75.0	(34.2-142.4)	Male	14	12.9	108.2	(59.1-181.6)
Female	10	9.9	100.5	(48.1-184.9)	Female	7	10.8	65.1	(26.1-134.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	28	36.4	76.8	(51.0-111.0)
Female	246	249.0	98.8	(86.8-112.0)	Female	33	33.0	100.0	(68.8-140.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.2	97.8	(42.1-192.7)	Male	32	28.0	114.2	(78.1-161.2)
<b><u>Colon / Rectum</u></b>					Female	25	13.7	183.1	(118.5-270.3)
Male	93	68.4	136.0	(109.8-166.6)	<b><u>Ovary</u></b>				
Female	73	72.5	100.7	(78.9-126.6)	Female	31	22.4	138.1	(93.8-196.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	16.7	95.7	(54.7-155.5)	Male	20	22.6	88.5	(54.0-136.7)
Female	5	4.7	107.3	(34.6-250.4)	Female	26	24.4	106.4	(69.5-155.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	4.7	106.9	(34.4-249.4)	Male	141	206.8	68.2	(57.4-80.4)
Female	2	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	15.1	79.6	(41.1-139.0)
Male	40	33.6	118.9	(84.9-161.9)	Female	13	9.4	138.8	(73.8-237.3)
Female	27	20.3	133.3	(87.8-194.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	8.3	131.9	(65.8-236.1)
Male	9	9.7	93.0	(42.4-176.6)	<b><u>Thyroid</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	8	14.8	54.0	(23.3-106.4)
<b><u>Leukemia</u></b>					Female	31	44.4	69.9	(47.5-99.2)
Male	23	25.8	89.2	(56.5-133.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	19.2	62.7	(32.3-109.4)	Female	53	56.5	93.9	(70.3-122.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	21.4	60.9	(32.4-104.1)	Male	762	829.1	91.9	(85.5-98.7)
Female	4	7.5	nc	(nc-nc)	Female	855	867.0	98.6	(92.1-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	142	116.2	122.2	(103.0-144.1)					
Female	141	125.8	112.1	(94.3-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	5.2	95.4	(30.7-222.6)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.5	134.1	(49.0-291.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	21	16.4	128.3	(79.4-196.1)
Female	0	0.1	nc	(nc-nc)	Female	13	16.9	76.8	(40.8-131.3)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.3	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	8.0	62.2	(20.0-145.2)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	2.3	220.3	(71.0-514.0)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	8.2	85.2	(34.1-175.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	27	32.8	82.4	(54.3-119.9)
Female	0	0.2	nc	(nc-nc)	Female	25	27.6	90.7	(58.7-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.7	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	13.0	176.9	(112.1-265.4)	Male	4	8.7	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	8	8.1	99.0	(42.6-195.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.8	63.9	(20.6-149.1)
Female	58	62.4	92.9	(70.5-120.1)	Female	7	8.1	86.6	(34.7-178.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	7	6.5	107.5	(43.1-221.4)
<b><u>Colon / Rectum</u></b>					Female	2	3.4	nc	(nc-nc)
Male	16	14.5	110.7	(63.2-179.8)	<b><u>Ovary</u></b>				
Female	14	17.8	78.8	(43.0-132.2)	Female	3	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	5	5.9	84.4	(27.2-196.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	48	47.0	102.1	(75.3-135.4)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.1	nc	(nc-nc)
Male	5	7.6	65.5	(21.1-153.0)	Female	1	2.3	nc	(nc-nc)
Female	5	4.9	101.3	(32.7-236.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	11.4	52.6	(19.2-114.4)
Male	8	5.4	147.5	(63.5-290.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.7	105.7	(34.0-246.6)	Female	13	14.3	91.1	(48.4-155.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.7	106.3	(34.2-248.0)	Male	176	178.6	98.6	(84.5-114.3)
Female	2	1.9	nc	(nc-nc)	Female	196	214.2	91.5	(79.1-105.2)
<b><u>Lung and Bronchus</u></b>									
Male	29	23.5	123.4	(82.6-177.2)					
Female	35	29.7	117.9	(82.1-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	85.2	(36.7-167.8)	Male	5	6.1	82.3	(26.5-192.2)
Female	5	3.2	155.4	(50.1-362.7)	Female	14	4.3	324.3	(177.1-544.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.9	(40.8-243.5)
Female	40	35.0	114.3	(81.7-155.7)	Female	1	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.4	114.5	(36.9-267.2)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	12	10.0	120.0	(62.0-209.7)	<b><u>Ovary</u></b>				
Female	5	9.5	52.7	(17.0-123.0)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	26	30.6	85.0	(55.5-124.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	7	5.1	137.7	(55.2-283.7)	Female	0	1.2	nc	(nc-nc)
Female	5	2.8	177.2	(57.1-413.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.0	133.1	(57.3-262.3)
Male	2	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	8	8.0	99.7	(42.9-196.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	107	122.2	87.6	(71.8-105.8)
Female	1	1.0	nc	(nc-nc)	Female	132	118.5	111.4	(93.2-132.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	17.0	58.9	(28.2-108.4)					
Female	10	17.3	57.7	(27.6-106.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	8	8.0	99.8	(43.0-196.6)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	9	8.6	104.1	(47.5-197.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	5	1.9	263.6	(85.0-615.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	29	34.7	83.6	(56.0-120.1)
Female	0	0.2	nc	(nc-nc)	Female	30	26.6	112.8	(76.1-161.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.9	nc	(nc-nc)					
Female	4	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	27.1	103.2	(68.5-149.1)	Male	29	16.6	174.5	(116.9-250.7)
Female	7	9.1	76.6	(30.7-157.8)	Female	18	11.1	161.8	(95.8-255.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.6	107.6	(34.7-251.2)	Male	5	5.4	93.3	(30.1-217.6)
Female	5	3.5	144.5	(46.6-337.1)	Female	4	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	13	14.9	87.4	(46.5-149.5)
Female	114	89.3	127.6	(105.3-153.3)	Female	9	12.0	74.7	(34.1-141.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	10	11.5	86.7	(41.5-159.4)
<b><u>Colon / Rectum</u></b>					Female	5	5.0	99.8	(32.1-232.8)
Male	19	28.5	66.7	(40.1-104.2)	<b><u>Ovary</u></b>				
Female	35	27.6	126.7	(88.2-176.2)	Female	15	8.1	185.1	(103.5-305.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	14	9.3	150.2	(82.0-252.0)
Female	0	1.7	nc	(nc-nc)	Female	8	9.3	85.7	(36.9-168.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	86	84.8	101.4	(81.1-125.2)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.2	nc	(nc-nc)
Male	13	13.8	94.2	(50.1-161.1)	Female	0	3.6	nc	(nc-nc)
Female	7	7.3	96.5	(38.6-198.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.7	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	13.7	87.6	(45.2-153.1)
Male	6	10.3	58.1	(21.2-126.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	7.0	nc	(nc-nc)	Female	25	20.2	124.0	(80.2-183.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.8	68.4	(25.0-149.0)	Male	295	338.6	87.1	(77.5-97.7)
Female	4	2.7	nc	(nc-nc)	Female	334	312.9	106.8	(95.6-118.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	47.3	40.1	(24.1-62.7)					
Female	27	45.6	59.1	(39.0-86.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	11	9.5	116.1	(57.9-207.8)	Female	0	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	65.1	(21.0-151.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	29	28.7	101.0	(67.6-145.1)
Female	0	0.3	nc	(nc-nc)	Female	26	29.9	86.9	(56.7-127.3)
<b><u>Lung and Bronchus</u></b>									
Male	4	3.8	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	7	4.5	155.2	(62.2-319.7)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	1.3	389.3	(125.5-908.5)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	18.0	88.9	(50.8-144.4)
Female	1	0.1	nc	(nc-nc)	Female	21	15.3	137.2	(84.9-209.7)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.6	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	10.3	106.5	(53.1-190.5)	Male	8	6.2	128.3	(55.2-252.8)
Female	2	3.2	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	27	33.2	81.4	(53.6-118.4)	Female	2	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	11	10.7	102.8	(51.3-184.0)	<b><u>Ovary</u></b>				
Female	11	9.6	115.0	(57.3-205.8)	Female	3	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	33	29.5	111.8	(77.0-157.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.3	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	7	7.7	91.1	(36.5-187.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	102	124.5	81.9	(66.8-99.4)
Female	0	1.0	nc	(nc-nc)	Female	94	114.3	82.2	(66.4-100.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	18.0	72.2	(38.4-123.5)					
Female	19	16.8	113.3	(68.2-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	35.1	105.3	(74.1-145.2)	Male	18	21.6	83.3	(49.3-131.7)
Female	15	12.3	121.6	(68.0-200.5)	Female	14	16.0	87.7	(47.9-147.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	6.1	196.4	(101.4-343.1)	Male	4	6.9	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	14	19.2	72.8	(39.7-122.1)
Female	141	123.9	113.8	(95.8-134.2)	Female	28	16.5	169.6	(112.7-245.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.0	nc	(nc-nc)	Male	14	14.7	95.1	(52.0-159.6)
<b><u>Colon / Rectum</u></b>					Female	7	6.8	103.3	(41.4-212.8)
Male	29	36.5	79.4	(53.2-114.1)	<b><u>Ovary</u></b>				
Female	39	37.1	105.2	(74.8-143.8)	Female	11	11.1	99.0	(49.3-177.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.8	125.2	(62.4-224.0)	Male	12	12.0	99.7	(51.5-174.2)
Female	2	2.3	nc	(nc-nc)	Female	9	12.5	72.2	(33.0-137.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	119	106.6	111.6	(92.5-133.6)
Female	4	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.0	62.2	(20.1-145.3)
Male	25	17.6	141.9	(91.8-209.5)	Female	7	4.8	144.5	(57.9-297.7)
Female	8	10.0	79.6	(34.3-156.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.8	130.3	(42.0-304.0)
Male	3	5.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	11	7.6	144.2	(71.9-258.0)
<b><u>Leukemia</u></b>					Female	23	21.4	107.4	(68.1-161.2)
Male	12	13.5	88.9	(45.9-155.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	9.7	133.9	(71.2-229.0)	Female	38	27.4	138.5	(98.0-190.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	11.2	107.3	(55.4-187.4)	Male	446	434.9	102.5	(93.2-112.5)
Female	6	3.7	161.1	(58.8-350.7)	Female	467	432.2	108.1	(98.5-118.3)
<b><u>Lung and Bronchus</u></b>									
Male	65	61.4	105.8	(81.6-134.9)					
Female	52	62.2	83.7	(62.5-109.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	43.1	132.2	(100.1-171.3)	Male	24	26.6	90.4	(57.9-134.5)
Female	17	15.4	110.1	(64.1-176.3)	Female	18	19.7	91.4	(54.1-144.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.6	92.2	(37.0-190.1)	Male	5	8.3	60.0	(19.3-140.0)
Female	7	6.1	115.5	(46.3-238.0)	Female	5	6.8	73.7	(23.7-171.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	21	24.0	87.6	(54.2-133.9)
Female	126	153.1	82.3	(68.6-98.0)	Female	17	20.6	82.6	(48.1-132.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.8	104.3	(33.6-243.3)	Male	16	18.3	87.3	(49.9-141.7)
<b><u>Colon / Rectum</u></b>					Female	13	8.6	151.7	(80.7-259.5)
Male	42	45.5	92.4	(66.6-124.9)	<b><u>Ovary</u></b>				
Female	44	46.2	95.2	(69.2-127.8)	Female	8	14.0	57.1	(24.6-112.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	10.8	101.7	(50.7-182.0)	Male	14	14.8	94.6	(51.7-158.8)
Female	2	3.0	nc	(nc-nc)	Female	8	15.8	50.7	(21.8-99.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	160	131.6	121.6	(103.5-141.9)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	9.9	121.7	(62.8-212.6)
Male	24	21.7	110.8	(71.0-164.9)	Female	7	6.1	115.5	(46.3-238.0)
Female	15	12.4	120.7	(67.5-199.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.7	105.9	(38.7-230.4)
Male	7	6.1	114.5	(45.9-235.8)	<b><u>Thyroid</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	8	9.7	82.3	(35.5-162.3)
<b><u>Leukemia</u></b>					Female	32	25.7	124.4	(85.1-175.7)
Male	17	16.8	101.4	(59.0-162.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	12.0	66.9	(28.8-131.9)	Female	37	35.0	105.7	(74.4-145.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	13.7	65.7	(30.0-124.8)	Male	544	537.2	101.3	(92.9-110.2)
Female	1	4.7	nc	(nc-nc)	Female	456	537.1	84.9	(77.3-93.1)
<b><u>Lung and Bronchus</u></b>									
Male	69	74.2	93.0	(72.4-117.7)					
Female	44	77.4	56.9	(41.3-76.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	33.0	106.1	(73.9-147.5)	Male	21	20.0	105.0	(65.0-160.5)
Female	11	12.1	91.1	(45.4-163.1)	Female	20	15.2	131.2	(80.1-202.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.6	160.8	(73.4-305.2)	Male	9	6.4	140.3	(64.0-266.4)
Female	4	4.7	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	20	17.9	111.4	(68.0-172.1)
Female	146	117.3	124.4	(105.1-146.3)	Female	15	15.9	94.1	(52.6-155.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.8	133.2	(42.9-310.8)	Male	14	13.2	106.1	(58.0-178.1)
<b><u>Colon / Rectum</u></b>					Female	12	6.5	183.7	(94.8-320.9)
Male	24	34.1	70.4	(45.1-104.8)	<b><u>Ovary</u></b>				
Female	29	36.3	79.8	(53.4-114.6)	Female	11	10.6	103.6	(51.6-185.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.0	74.8	(27.3-162.9)	Male	11	11.0	99.8	(49.7-178.5)
Female	0	2.3	nc	(nc-nc)	Female	17	12.2	139.1	(81.0-222.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	94	93.8	100.2	(81.0-122.6)
Female	3	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.5	120.3	(54.9-228.3)
Male	14	16.1	86.8	(47.4-145.6)	Female	7	4.7	147.6	(59.1-304.1)
Female	12	9.6	124.6	(64.3-217.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.7	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	5	7.0	71.4	(23.0-166.7)
<b><u>Leukemia</u></b>					Female	30	20.0	149.8	(101.1-213.9)
Male	9	12.6	71.5	(32.6-135.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.4	74.7	(29.9-153.9)	Female	25	25.8	96.9	(62.7-143.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	10.0	109.9	(54.8-196.7)	Male	390	398.2	97.9	(88.5-108.2)
Female	6	3.6	167.4	(61.1-364.5)	Female	468	415.0	112.8	(102.8-123.5)
<b><u>Lung and Bronchus</u></b>									
Male	50	56.7	88.2	(65.5-116.3)					
Female	77	60.6	127.1	(100.3-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	5	3.2	155.1	(50.0-361.9)
Female	3	2.1	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	19	24.6	77.4	(46.6-120.8)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	5.3	112.6	(41.1-245.2)	<b><u>Ovary</u></b>				
Female	5	6.3	80.0	(25.8-186.6)	Female	0	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	19	19.4	97.9	(58.9-152.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	5	3.1	162.4	(52.3-379.0)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	54	68.0	79.5	(59.7-103.7)
Female	0	0.7	nc	(nc-nc)	Female	60	80.8	74.3	(56.7-95.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.6	nc	(nc-nc)					
Female	5	11.4	43.7	(14.1-101.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	28.9	145.4	(104.8-196.6)	Male	37	16.2	228.2	(160.7-314.6)
Female	15	10.4	144.8	(81.0-238.9)	Female	20	11.7	171.6	(104.8-265.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	10	5.3	187.7	(89.8-345.2)
Female	1	3.6	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	15	14.2	105.5	(59.0-174.1)
Female	114	96.2	118.5	(97.7-142.3)	Female	10	13.3	75.4	(36.1-138.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	16	10.1	159.0	(90.8-258.2)
<b><u>Colon / Rectum</u></b>					Female	3	5.4	nc	(nc-nc)
Male	29	27.4	105.8	(70.9-152.0)	<b><u>Ovary</u></b>				
Female	24	28.5	84.3	(54.0-125.5)	Female	13	8.6	150.4	(80.0-257.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	6.8	146.9	(70.3-270.2)	Male	17	9.5	179.1	(104.3-286.8)
Female	5	2.0	251.6	(81.1-587.2)	Female	11	10.2	107.7	(53.7-192.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	108	81.8	132.0	(108.3-159.4)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	6.3	nc	(nc-nc)
Male	10	12.6	79.6	(38.1-146.4)	Female	2	3.7	nc	(nc-nc)
Female	6	8.2	73.1	(26.7-159.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	17	13.1	129.4	(75.3-207.2)
Male	14	10.1	139.2	(76.0-233.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.3	95.8	(38.4-197.3)	Female	20	22.8	87.6	(53.5-135.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.1	98.7	(42.5-194.6)	Male	401	331.3	121.0	(109.5-133.5)
Female	4	3.1	nc	(nc-nc)	Female	366	342.3	106.9	(96.3-118.5)
<b><u>Lung and Bronchus</u></b>									
Male	44	50.7	86.9	(63.1-116.6)					
Female	54	56.3	95.9	(72.1-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.8	71.6	(28.7-147.4)	Male	5	5.9	84.9	(27.3-198.0)
Female	1	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	94.7	(30.5-220.9)
Female	16	29.6	54.1	(30.9-87.9)	Female	1	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	15	10.2	147.0	(82.2-242.5)	<b><u>Ovary</u></b>				
Female	5	8.2	60.9	(19.6-142.1)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	30	28.7	104.4	(70.4-149.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	6	4.8	126.0	(46.0-274.2)	Female	0	1.1	nc	(nc-nc)
Female	5	2.4	211.3	(68.1-493.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.3	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	7	6.6	106.1	(42.5-218.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	110	119.0	92.5	(76.0-111.4)
Female	1	0.9	nc	(nc-nc)	Female	75	100.3	74.7	(58.8-93.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	16.9	59.2	(28.4-109.0)					
Female	14	14.2	98.6	(53.9-165.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.1	84.4	(30.8-183.8)	Male	6	5.2	116.3	(42.5-253.1)
Female	4	2.0	nc	(nc-nc)	Female	6	3.8	156.5	(57.1-340.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	29	31.4	92.2	(61.7-132.5)	Female	2	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	5	8.4	59.3	(19.1-138.3)	<b><u>Ovary</u></b>				
Female	5	6.5	77.0	(24.8-179.6)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	28.4	84.7	(54.2-126.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	8	4.7	170.2	(73.3-335.4)	Female	0	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.7	134.1	(61.2-254.7)
Male	1	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	9	7.1	126.6	(57.8-240.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	101	105.8	95.5	(77.8-116.0)
Female	1	0.7	nc	(nc-nc)	Female	98	95.5	102.6	(83.3-125.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	13.4	104.5	(57.1-175.3)					
Female	11	11.8	93.3	(46.5-166.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	11	4.7	234.9	(117.1-420.4)
Female	0	2.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.2	168.7	(67.6-347.5)
Female	27	25.1	107.4	(70.8-156.3)	Female	3	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	7.9	75.7	(27.6-164.7)	<b><u>Ovary</u></b>				
Female	5	6.2	80.2	(25.9-187.2)	Female	0	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	27	23.4	115.4	(76.0-167.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	115.1	(37.1-268.6)
Male	1	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	1	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	92	94.8	97.0	(78.2-119.0)
Female	0	0.7	nc	(nc-nc)	Female	63	81.2	77.6	(59.6-99.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.6	58.8	(25.3-115.8)					
Female	6	11.5	52.2	(19.1-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	29.9	133.9	(95.6-182.3)	Male	10	20.1	49.7	(23.8-91.4)
Female	16	10.4	153.7	(87.8-249.5)	Female	15	15.8	95.0	(53.2-156.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.3	110.7	(44.3-228.0)	Male	7	6.3	111.7	(44.7-230.1)
Female	3	4.9	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	17.9	83.7	(46.8-138.1)
Female	138	123.2	112.0	(94.1-132.3)	Female	10	15.0	66.7	(32.0-122.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.3	115.3	(37.2-269.1)	Male	8	15.2	52.8	(22.7-104.0)
<b><u>Colon / Rectum</u></b>					Female	10	6.4	155.9	(74.6-286.7)
Male	38	33.3	114.2	(80.8-156.8)	<b><u>Ovary</u></b>				
Female	48	31.8	151.0	(111.4-200.3)	Female	12	10.8	110.6	(57.1-193.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.4	155.5	(82.7-266.0)	Male	7	10.8	64.7	(25.9-133.4)
Female	3	2.1	nc	(nc-nc)	Female	12	10.4	115.0	(59.4-200.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	99	108.7	91.1	(74.0-110.9)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.2	83.8	(30.6-182.3)
Male	20	17.5	114.0	(69.6-176.0)	Female	5	4.1	123.3	(39.7-287.7)
Female	7	9.6	73.0	(29.3-150.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.5	nc	(nc-nc)
Male	8	4.9	164.1	(70.6-323.3)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	7	8.3	84.6	(33.9-174.4)
<b><u>Leukemia</u></b>					Female	28	23.7	118.0	(78.4-170.5)
Male	18	12.5	144.2	(85.4-228.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.7	114.4	(54.8-210.5)	Female	13	28.2	46.1	(24.5-78.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.3	nc	(nc-nc)	Male	408	412.2	99.0	(89.6-109.1)
Female	5	3.4	145.9	(47.0-340.4)	Female	461	408.6	112.8	(102.8-123.6)
<b><u>Lung and Bronchus</u></b>									
Male	61	54.7	111.6	(85.4-143.4)					
Female	75	55.9	134.1	(105.5-168.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.2	107.1	(55.3-187.0)	Male	5	7.3	68.6	(22.1-160.0)
Female	3	3.1	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	42	39.6	106.0	(76.4-143.3)	Female	5	4.6	108.4	(34.9-252.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	12	12.0	100.1	(51.7-174.9)	<b><u>Ovary</u></b>				
Female	11	9.5	115.4	(57.6-206.6)	Female	8	3.4	233.5	(100.5-460.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	5	3.9	129.8	(41.8-303.0)
Female	2	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	33	34.5	95.5	(65.8-134.2)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.6	190.4	(61.3-444.2)
Male	8	6.1	132.2	(56.9-260.5)	Female	0	1.2	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.8	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	8.0	138.1	(68.8-247.1)
Male	9	4.6	194.5	(88.8-369.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.7	185.0	(59.6-431.7)	Female	17	8.9	190.3	(110.8-304.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.8	nc	(nc-nc)	Male	149	144.7	103.0	(87.1-120.9)
Female	1	1.0	nc	(nc-nc)	Female	158	128.1	123.3	(104.9-144.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	19.9	130.5	(85.2-191.2)					
Female	26	17.0	152.6	(99.6-223.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	18	14.1	127.6	(75.6-201.7)	Female	2	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.7	nc	(nc-nc)
Male	5	3.5	144.6	(46.6-337.5)	<b><u>Ovary</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	12.3	57.1	(22.9-117.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.7	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	39	43.3	90.1	(64.0-123.1)
Female	0	0.4	nc	(nc-nc)	Female	45	45.1	99.8	(72.8-133.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.5	nc	(nc-nc)					
Female	8	5.7	140.2	(60.4-276.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	18.0	138.6	(89.7-204.6)	Male	29	11.3	255.7	(171.2-367.3)
Female	1	6.7	nc	(nc-nc)	Female	15	9.1	164.4	(91.9-271.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	7	3.7	189.8	(76.0-391.0)
Female	1	2.9	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	18	10.2	176.6	(104.6-279.1)
Female	82	74.5	110.0	(87.5-136.5)	Female	4	9.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	6	8.4	71.4	(26.1-155.5)
<b><u>Colon / Rectum</u></b>					Female	4	4.0	nc	(nc-nc)
Male	10	19.3	51.9	(24.8-95.4)	<b><u>Ovary</u></b>				
Female	14	20.4	68.5	(37.4-114.9)	Female	6	6.6	90.7	(33.1-197.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.9	122.9	(44.9-267.5)	Male	5	6.3	78.8	(25.4-183.9)
Female	1	1.3	nc	(nc-nc)	Female	6	6.8	88.4	(32.3-192.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	73	62.9	116.1	(91.0-146.0)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	4.2	nc	(nc-nc)
Male	16	9.9	161.3	(92.2-262.0)	Female	2	2.6	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	12.5	79.8	(38.2-146.7)
Male	7	7.1	99.2	(39.7-204.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.3	nc	(nc-nc)	Female	8	17.0	47.1	(20.3-92.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.3	nc	(nc-nc)	Male	261	237.0	110.1	(97.2-124.4)
Female	0	2.1	nc	(nc-nc)	Female	207	249.3	83.0	(72.1-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	28	32.4	86.4	(57.4-124.8)					
Female	17	34.9	48.6	(28.3-77.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.2	130.9	(74.8-212.6)	Male	10	8.4	119.5	(57.2-219.8)
Female	6	5.8	102.6	(37.5-223.4)	Female	8	8.3	96.2	(41.4-189.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.5	106.3	(45.8-209.5)
Female	47	66.9	70.3	(51.6-93.4)	Female	11	8.3	132.8	(66.2-237.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	8	6.4	124.6	(53.6-245.5)
<b><u>Colon / Rectum</u></b>					Female	1	3.5	nc	(nc-nc)
Male	17	14.1	121.0	(70.4-193.7)	<b><u>Ovary</u></b>				
Female	11	17.7	62.3	(31.0-111.4)	Female	6	5.9	101.5	(37.1-220.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.4	175.2	(64.0-381.3)	Male	2	4.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	5.8	137.2	(59.1-270.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	46	44.7	102.8	(75.3-137.2)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	12	7.5	160.5	(82.8-280.3)	Female	2	2.2	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	5	3.6	138.3	(44.6-322.7)
<b><u>Leukemia</u></b>					Female	11	12.1	91.1	(45.4-163.0)
Male	3	5.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.7	nc	(nc-nc)	Female	11	15.3	71.9	(35.8-128.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.6	109.1	(35.2-254.6)	Male	192	171.0	112.3	(97.0-129.3)
Female	0	1.9	nc	(nc-nc)	Female	183	223.2	82.0	(70.5-94.8)
<b><u>Lung and Bronchus</u></b>									
Male	27	22.4	120.7	(79.6-175.7)					
Female	24	31.6	75.8	(48.6-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	8	10.0	80.0	(34.4-157.6)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.5	84.4	(36.4-166.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	29	35.3	82.1	(55.0-117.9)
Female	0	0.3	nc	(nc-nc)	Female	29	32.8	88.4	(59.2-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.7	nc	(nc-nc)					
Female	5	4.6	108.6	(35.0-253.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	20.2	89.2	(52.8-141.0)	Male	19	12.3	154.1	(92.7-240.6)
Female	5	8.6	58.3	(18.8-136.0)	Female	10	10.4	96.2	(46.1-177.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	11.1	125.9	(68.8-211.2)
Female	75	80.7	92.9	(73.1-116.5)	Female	9	11.3	80.0	(36.5-151.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	9	8.7	104.0	(47.5-197.4)
<b><u>Colon / Rectum</u></b>					Female	5	4.6	108.7	(35.0-253.6)
Male	21	21.4	98.2	(60.8-150.1)	<b><u>Ovary</u></b>				
Female	23	25.8	89.0	(56.4-133.5)	Female	12	7.4	163.0	(84.1-284.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	5	6.9	72.1	(23.2-168.4)
Female	2	1.6	nc	(nc-nc)	Female	11	8.8	125.2	(62.4-224.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	53	63.2	83.8	(62.8-109.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.6	107.8	(34.7-251.5)
Male	13	10.3	126.2	(67.1-215.9)	Female	4	3.4	nc	(nc-nc)
Female	8	6.7	119.9	(51.6-236.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.1	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	12.8	62.4	(26.9-123.0)
Male	7	7.7	90.5	(36.3-186.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.6	nc	(nc-nc)	Female	16	18.0	88.8	(50.7-144.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	234	252.4	92.7	(81.2-105.4)
Female	1	2.6	nc	(nc-nc)	Female	273	288.8	94.5	(83.7-106.5)
<b><u>Lung and Bronchus</u></b>									
Male	36	34.9	103.0	(72.1-142.6)					
Female	51	42.7	119.5	(89.0-157.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.1	89.9	(43.0-165.3)	Male	8	6.4	124.7	(53.7-245.8)
Female	4	3.6	nc	(nc-nc)	Female	13	4.2	307.7	(163.7-526.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	45	35.8	125.8	(91.8-168.4)	Female	7	4.7	149.6	(59.9-308.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.0	nc	(nc-nc)
Male	11	10.8	101.6	(50.7-181.9)	<b><u>Ovary</u></b>				
Female	12	9.9	121.5	(62.7-212.2)	Female	4	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	6	3.5	169.5	(61.9-369.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	42	36.6	114.8	(82.7-155.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.9	nc	(nc-nc)
Male	9	3.9	230.0	(104.9-436.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	7	8.7	80.7	(32.3-166.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	141	135.5	104.0	(87.6-122.7)
Female	1	1.1	nc	(nc-nc)	Female	140	123.3	113.5	(95.5-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	25	20.0	124.9	(80.8-184.4)					
Female	14	19.9	70.4	(38.4-118.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	18.4	49.0	(22.3-93.0)	Male	9	12.0	74.9	(34.2-142.1)
Female	2	7.0	nc	(nc-nc)	Female	7	9.7	72.3	(29.0-149.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	10.7	84.5	(38.5-160.3)
Female	66	73.9	89.3	(69.1-113.6)	Female	11	9.6	114.6	(57.1-205.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	10	8.8	113.8	(54.5-209.2)
<b><u>Colon / Rectum</u></b>					Female	7	4.0	174.8	(70.0-360.1)
Male	32	20.1	159.3	(108.9-224.8)	<b><u>Ovary</u></b>				
Female	25	21.0	119.1	(77.0-175.8)	Female	3	6.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	9	6.9	129.7	(59.2-246.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	52	62.2	83.6	(62.4-109.6)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	7	10.1	69.0	(27.6-142.2)	Female	2	2.7	nc	(nc-nc)
Female	8	6.0	134.0	(57.7-264.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.7	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	13.8	58.1	(25.0-114.5)
Male	7	7.3	95.4	(38.2-196.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.5	nc	(nc-nc)	Female	19	16.8	113.3	(68.2-176.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.6	nc	(nc-nc)	Male	206	243.5	84.6	(73.4-97.0)
Female	3	2.2	nc	(nc-nc)	Female	231	254.8	90.7	(79.3-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	29	32.8	88.3	(59.1-126.8)					
Female	34	36.4	93.3	(64.6-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	20.9	115.1	(73.7-171.2)	Male	19	14.2	134.1	(80.7-209.5)
Female	9	7.2	124.2	(56.7-235.8)	Female	18	11.4	157.6	(93.4-249.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	131.8	(48.1-286.9)	Male	5	4.4	112.5	(36.3-262.5)
Female	4	3.7	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	8	12.7	62.9	(27.1-123.9)
Female	117	89.0	131.5	(108.8-157.6)	Female	14	10.7	130.8	(71.5-219.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	10	10.8	92.4	(44.2-169.9)
<b><u>Colon / Rectum</u></b>					Female	3	4.6	nc	(nc-nc)
Male	18	23.3	77.3	(45.8-122.2)	<b><u>Ovary</u></b>				
Female	31	22.3	139.0	(94.4-197.3)	Female	9	7.8	115.4	(52.7-219.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.9	101.0	(36.9-219.9)	Male	8	7.6	105.6	(45.5-208.1)
Female	3	1.4	nc	(nc-nc)	Female	8	7.2	111.3	(47.9-219.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	71	78.5	90.4	(70.6-114.1)
Female	2	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.0	99.2	(32.0-231.4)
Male	15	12.6	118.8	(66.4-195.9)	Female	3	2.9	nc	(nc-nc)
Female	6	6.8	87.7	(32.0-191.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	10	6.0	167.1	(80.0-307.4)
<b><u>Leukemia</u></b>					Female	19	17.9	106.2	(63.9-165.8)
Male	13	8.9	146.6	(78.0-250.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.3	111.3	(44.6-229.3)	Female	15	20.1	74.5	(41.7-122.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	8.0	125.5	(60.1-230.8)	Male	312	293.4	106.3	(94.9-118.8)
Female	3	2.4	nc	(nc-nc)	Female	351	292.5	120.0	(107.8-133.2)
<b><u>Lung and Bronchus</u></b>									
Male	47	38.6	121.7	(89.4-161.8)					
Female	47	39.2	119.8	(88.0-159.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.0	99.3	(39.8-204.7)	Male	12	4.5	269.2	(138.9-470.3)
Female	2	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	19.0	126.1	(80.8-187.7)	Female	3	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.0	nc	(nc-nc)
Male	9	7.5	120.2	(54.9-228.3)	<b><u>Ovary</u></b>				
Female	3	5.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	30	25.6	117.0	(78.9-167.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.3	180.9	(66.1-393.8)
Male	2	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	87	93.7	92.9	(74.4-114.6)
Female	0	0.5	nc	(nc-nc)	Female	71	62.7	113.3	(88.5-142.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.7	39.5	(12.7-92.1)					
Female	11	8.8	125.5	(62.6-224.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	5	2.2	229.2	(73.9-534.9)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	64.5	(20.8-150.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	21	27.7	75.8	(46.9-115.8)
Female	0	0.3	nc	(nc-nc)	Female	16	27.4	58.4	(33.4-94.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.9	nc	(nc-nc)					
Female	3	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	15	23.9	62.7	(35.1-103.4)
Female	0	0.2	nc	(nc-nc)	Female	16	24.7	64.9	(37.1-105.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.2	nc	(nc-nc)					
Female	2	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.9	127.7	(41.1-298.0)	Male	5	2.6	190.7	(61.4-445.0)
Female	1	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	13	16.6	78.5	(41.8-134.2)	Female	2	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	5	2.0	246.1	(79.3-574.3)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.7	nc	(nc-nc)	Female	5	1.4	348.4	(112.3-813.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.0	46.6	(18.7-96.0)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	55	54.7	100.6	(75.7-130.9)
Female	0	0.4	nc	(nc-nc)	Female	54	52.7	102.4	(77.0-133.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	7.2	138.1	(66.1-254.1)					
Female	8	7.3	109.7	(47.2-216.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	37.7	76.9	(51.5-110.5)	Male	19	25.2	75.3	(45.3-117.5)
Female	10	13.6	73.7	(35.3-135.6)	Female	6	20.8	28.9	(10.6-62.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	8.1	nc	(nc-nc)	Male	9	7.7	117.6	(53.7-223.3)
Female	3	6.4	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	15	22.5	66.6	(37.3-109.9)
Female	137	153.3	89.4	(75.0-105.6)	Female	18	19.3	93.3	(55.2-147.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	5.8	258.6	(144.6-426.5)	Male	18	17.7	101.9	(60.4-161.1)
<b><u>Colon / Rectum</u></b>					Female	9	8.0	112.0	(51.1-212.6)
Male	38	41.6	91.4	(64.6-125.4)	<b><u>Ovary</u></b>				
Female	33	42.3	78.0	(53.7-109.6)	Female	10	13.6	73.3	(35.1-134.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	9.8	112.7	(56.2-201.6)	Male	11	13.2	83.5	(41.6-149.5)
Female	2	2.6	nc	(nc-nc)	Female	16	13.6	118.0	(67.4-191.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	104	118.2	88.0	(71.9-106.6)
Female	5	2.9	173.4	(55.9-404.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	8.9	168.3	(94.1-277.6)
Male	25	21.0	119.3	(77.2-176.1)	Female	6	5.4	110.9	(40.5-241.5)
Female	18	12.2	147.5	(87.4-233.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	7.4	95.2	(38.1-196.1)
Male	6	5.6	106.3	(38.8-231.3)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	8	10.5	76.3	(32.9-150.3)
<b><u>Leukemia</u></b>					Female	24	32.3	74.2	(47.6-110.5)
Male	10	16.1	62.3	(29.8-114.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	11.7	110.7	(58.9-189.3)	Female	27	33.3	81.1	(53.5-118.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	12.9	115.9	(64.8-191.1)	Male	454	496.0	91.5	(83.3-100.3)
Female	9	4.3	211.5	(96.5-401.5)	Female	500	521.9	95.8	(87.6-104.6)
<b><u>Lung and Bronchus</u></b>									
Male	79	66.8	118.2	(93.6-147.3)					
Female	98	70.6	138.8	(112.7-169.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	20.0	144.6	(96.9-207.7)	Male	6	12.7	47.4	(17.3-103.1)
Female	16	8.3	193.2	(110.3-313.7)	Female	11	10.6	103.9	(51.8-185.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	5	4.0	123.9	(39.9-289.1)
Female	5	3.2	155.3	(50.0-362.3)	Female	0	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	7	11.3	61.9	(24.8-127.6)
Female	79	81.1	97.4	(77.1-121.4)	Female	15	11.0	136.5	(76.4-225.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	6	9.3	64.6	(23.6-140.6)
<b><u>Colon / Rectum</u></b>					Female	4	4.6	nc	(nc-nc)
Male	13	21.5	60.5	(32.2-103.4)	<b><u>Ovary</u></b>				
Female	21	25.1	83.8	(51.9-128.1)	Female	12	7.5	160.5	(82.9-280.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	10	8.5	118.0	(56.5-217.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	75	70.0	107.2	(84.3-134.4)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.7	128.1	(46.8-278.7)
Male	17	10.9	156.1	(90.9-249.9)	Female	3	3.3	nc	(nc-nc)
Female	10	6.6	151.0	(72.3-277.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	4.7	105.6	(34.0-246.3)
<b><u>Leukemia</u></b>					Female	14	13.8	101.7	(55.6-170.7)
Male	10	7.7	130.3	(62.4-239.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.5	138.8	(63.3-263.5)	Female	17	18.5	92.0	(53.6-147.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.9	nc	(nc-nc)	Male	274	263.0	104.2	(92.2-117.3)
Female	1	2.5	nc	(nc-nc)	Female	300	286.4	104.7	(93.2-117.3)
<b><u>Lung and Bronchus</u></b>									
Male	50	35.8	139.5	(103.5-183.9)					
Female	46	40.9	112.5	(82.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	102	88.3	115.6	(94.2-140.3)	Male	29	57.1	50.8	(34.0-73.0)
Female	37	38.0	97.3	(68.5-134.1)	Female	25	51.6	48.4	(31.3-71.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	17.5	102.9	(60.9-162.6)	Male	13	17.7	73.4	(39.1-125.6)
Female	11	16.1	68.3	(34.1-122.2)	Female	16	16.8	95.0	(54.3-154.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	44	51.1	86.1	(62.6-115.6)
Female	297	390.4	76.1	(67.7-85.2)	Female	54	52.0	103.9	(78.1-135.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	13.3	127.8	(74.4-204.7)	Male	39	40.6	96.0	(68.3-131.3)
<b><u>Colon / Rectum</u></b>					Female	15	21.6	69.5	(38.9-114.6)
Male	115	95.4	120.6	(99.5-144.7)	<b><u>Ovary</u></b>				
Female	119	114.8	103.6	(85.8-124.0)	Female	19	35.5	53.5	(32.2-83.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	23.1	77.8	(46.1-122.9)	Male	33	30.9	106.7	(73.4-149.8)
Female	4	7.3	nc	(nc-nc)	Female	39	38.5	101.2	(72.0-138.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	12	7.2	165.8	(85.5-289.6)	Male	287	292.7	98.1	(87.0-110.1)
Female	6	6.5	92.4	(33.7-201.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	36	20.7	173.7	(121.6-240.5)
Male	47	48.3	97.3	(71.5-129.5)	Female	29	14.9	194.5	(130.8-279.4)
Female	31	31.7	97.7	(66.4-138.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	14	13.6	103.1	(56.3-173.0)
Male	23	13.5	170.8	(108.2-256.3)	<b><u>Thyroid</u></b>				
Female	12	4.8	251.7	(129.9-439.8)	Male	18	22.4	80.3	(47.6-126.9)
<b><u>Leukemia</u></b>					Female	77	72.3	106.5	(84.0-133.1)
Male	34	36.0	94.4	(65.3-131.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	34	30.9	110.0	(76.2-153.8)	Female	99	87.6	113.1	(91.9-137.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	32	30.1	106.5	(72.8-150.3)	Male	1243	1157.9	107.3	(101.5-113.5)
Female	14	11.7	119.7	(65.4-200.9)	Female	1311	1365.9	96.0	(90.9-101.3)
<b><u>Lung and Bronchus</u></b>									
Male	231	157.4	146.8	(128.4-167.0)					
Female	218	195.0	111.8	(97.4-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	58.7	91.9	(69.1-119.9)	Male	35	33.7	103.9	(72.3-144.4)
Female	13	21.0	61.9	(32.9-105.8)	Female	41	24.5	167.1	(119.9-226.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	8.6	162.9	(89.0-273.4)	Male	7	11.0	63.8	(25.6-131.5)
Female	9	7.4	121.4	(55.4-230.5)	Female	7	9.2	76.0	(30.4-156.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	31	29.8	104.1	(70.7-147.8)
Female	216	200.0	108.0	(94.1-123.4)	Female	24	27.2	88.1	(56.4-131.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.6	nc	(nc-nc)	Male	24	22.0	109.1	(69.9-162.3)
<b><u>Colon / Rectum</u></b>					Female	7	11.3	61.9	(24.8-127.6)
Male	53	57.6	92.0	(68.9-120.4)	<b><u>Ovary</u></b>				
Female	52	59.9	86.9	(64.9-113.9)	Female	24	18.2	132.2	(84.7-196.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.3	91.2	(48.5-155.9)	Male	15	19.7	76.1	(42.6-125.5)
Female	6	4.0	149.4	(54.6-325.3)	Female	17	21.0	81.1	(47.2-129.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	195	175.6	111.1	(96.0-127.8)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	13.0	77.1	(36.9-141.9)
Male	30	26.8	111.8	(75.4-159.6)	Female	5	7.7	64.7	(20.8-151.0)
Female	16	16.8	95.4	(54.5-154.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.6	nc	(nc-nc)
Male	9	8.2	110.1	(50.2-209.0)	<b><u>Thyroid</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.4)
<b><u>Leukemia</u></b>					Female	14	28.8	48.6	(26.5-81.5)
Male	18	20.9	86.0	(50.9-135.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	15.2	59.3	(27.1-112.6)	Female	39	47.2	82.6	(58.7-112.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	17.3	98.5	(57.3-157.6)	Male	667	694.7	96.0	(88.9-103.6)
Female	3	6.3	nc	(nc-nc)	Female	667	706.2	94.4	(87.4-101.9)
<b><u>Lung and Bronchus</u></b>									
Male	65	103.3	62.9	(48.6-80.2)					
Female	109	110.8	98.4	(80.8-118.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	39.6	103.4	(74.2-140.3)	Male	15	25.6	58.5	(32.7-96.5)
Female	14	14.9	93.8	(51.3-157.5)	Female	13	20.7	62.7	(33.4-107.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	8.1	nc	(nc-nc)	Male	12	8.0	150.2	(77.5-262.5)
Female	9	6.5	138.4	(63.1-262.7)	Female	7	6.6	105.9	(42.4-218.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	16	22.9	69.7	(39.8-113.2)
Female	133	155.9	85.3	(71.4-101.1)	Female	15	20.4	73.6	(41.1-121.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.3	169.5	(77.3-321.8)	Male	24	18.0	133.6	(85.5-198.7)
<b><u>Colon / Rectum</u></b>					Female	11	8.5	129.4	(64.5-231.5)
Male	34	42.3	80.3	(55.6-112.2)	<b><u>Ovary</u></b>				
Female	43	44.4	96.9	(70.1-130.5)	Female	16	14.1	113.2	(64.6-183.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	10.4	86.9	(39.7-165.0)	Male	11	13.8	79.6	(39.7-142.5)
Female	2	2.9	nc	(nc-nc)	Female	7	15.0	46.8	(18.7-96.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	3.5	142.1	(45.8-331.6)	Male	101	129.7	77.9	(63.4-94.6)
Female	0	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	9.2	151.8	(82.9-254.8)
Male	19	21.5	88.6	(53.3-138.3)	Female	5	5.7	87.0	(28.0-203.1)
Female	9	12.7	70.7	(32.3-134.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.5	92.9	(33.9-202.2)
Male	1	6.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	4	10.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	27	29.5	91.6	(60.3-133.2)
Male	12	16.5	72.9	(37.6-127.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.2	90.0	(44.8-161.0)	Female	29	35.3	82.1	(55.0-118.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	13.5	96.3	(51.2-164.7)	Male	478	518.8	92.1	(84.1-100.8)
Female	5	4.6	108.3	(34.9-252.7)	Female	492	542.7	90.7	(82.8-99.0)
<b><u>Lung and Bronchus</u></b>									
Male	95	71.2	133.4	(107.9-163.1)					
Female	84	78.1	107.6	(85.8-133.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	9.7	92.6	(42.3-175.8)
Female	0	0.1	nc	(nc-nc)	Female	11	12.1	90.9	(45.3-162.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.3	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.5	68.5	(35.4-119.7)	Male	22	11.4	193.6	(121.3-293.2)
Female	4	6.2	nc	(nc-nc)	Female	12	9.2	130.3	(67.2-227.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	144.2	(46.5-336.6)	Male	2	3.6	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.2	117.4	(60.6-205.0)
Female	92	73.9	124.5	(100.4-152.7)	Female	7	8.9	78.2	(31.3-161.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	7	8.3	84.8	(34.0-174.8)
<b><u>Colon / Rectum</u></b>					Female	0	3.8	nc	(nc-nc)
Male	20	19.3	103.6	(63.2-160.0)	<b><u>Ovary</u></b>				
Female	20	18.4	108.6	(66.3-167.7)	Female	10	6.4	155.1	(74.2-285.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.6	107.5	(34.7-250.9)	Male	3	6.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	6	6.1	98.9	(36.1-215.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.4	365.9	(117.9-853.9)	Male	66	58.0	113.8	(88.0-144.7)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	4.1	169.6	(68.0-349.5)
Male	9	9.7	92.5	(42.2-175.6)	Female	1	2.3	nc	(nc-nc)
Female	6	5.8	104.2	(38.1-226.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	4.5	177.0	(76.2-348.7)
<b><u>Leukemia</u></b>					Female	19	13.8	137.9	(83.0-215.4)
Male	8	7.1	112.5	(48.4-221.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.1	137.4	(55.1-283.2)	Female	21	17.1	122.6	(75.9-187.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	251	230.5	108.9	(95.8-123.2)
Female	1	2.1	nc	(nc-nc)	Female	276	243.4	113.4	(100.4-127.6)
<b><u>Lung and Bronchus</u></b>									
Male	32	31.1	103.0	(70.4-145.4)					
Female	35	34.3	102.0	(71.0-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	66.5	84.2	(63.6-109.4)	Male	42	43.6	96.3	(69.4-130.1)
Female	29	26.0	111.6	(74.7-160.3)	Female	29	37.5	77.4	(51.8-111.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	13.4	81.9	(40.8-146.5)	Male	17	13.5	126.3	(73.5-202.2)
Female	5	11.7	42.6	(13.7-99.3)	Female	13	11.6	112.1	(59.6-191.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	42	39.0	107.8	(77.7-145.7)
Female	273	282.1	96.8	(85.6-109.0)	Female	31	36.2	85.7	(58.2-121.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	10.1	177.8	(105.3-281.1)	Male	31	30.8	100.6	(68.3-142.8)
<b><u>Colon / Rectum</u></b>					Female	7	15.1	46.3	(18.6-95.4)
Male	74	72.4	102.2	(80.3-128.4)	<b><u>Ovary</u></b>				
Female	85	79.1	107.4	(85.8-132.8)	Female	28	25.3	110.7	(73.5-160.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	17.4	86.3	(48.3-142.4)	Male	29	23.3	124.6	(83.4-178.9)
Female	7	5.0	140.4	(56.3-289.3)	Female	29	26.1	110.9	(74.3-159.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	197	216.7	90.9	(78.7-104.5)
Female	9	5.0	181.6	(82.9-344.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	15.7	140.1	(87.8-212.1)
Male	46	36.7	125.2	(91.6-167.0)	Female	11	10.2	107.4	(53.5-192.1)
Female	15	22.6	66.5	(37.2-109.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	11.0	81.9	(37.4-155.6)
Male	4	10.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	3.3	nc	(nc-nc)	Male	22	17.6	125.2	(78.5-189.6)
<b><u>Leukemia</u></b>					Female	56	55.6	100.7	(76.1-130.8)
Male	29	27.4	105.9	(70.9-152.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	21.8	96.4	(59.6-147.3)	Female	56	62.7	89.3	(67.5-116.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	28	22.8	122.6	(81.4-177.2)	Male	848	873.4	97.1	(90.7-103.8)
Female	8	8.1	98.9	(42.6-194.8)	Female	969	968.3	100.1	(93.9-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	109	117.7	92.6	(76.0-111.7)					
Female	138	133.9	103.1	(86.6-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	27.0	103.7	(68.9-149.9)	Male	16	18.4	86.8	(49.6-141.0)
Female	9	9.9	91.2	(41.6-173.1)	Female	16	15.5	103.0	(58.9-167.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.1	82.1	(26.5-191.7)	Male	9	5.7	158.1	(72.1-300.1)
Female	5	5.0	100.8	(32.5-235.2)	Female	4	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	14	16.6	84.1	(46.0-141.2)
Female	130	121.4	107.1	(89.5-127.2)	Female	14	14.4	97.3	(53.2-163.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.4	136.0	(49.7-296.0)	Male	17	13.7	123.8	(72.1-198.2)
<b><u>Colon / Rectum</u></b>					Female	3	6.2	nc	(nc-nc)
Male	25	30.7	81.4	(52.7-120.2)	<b><u>Ovary</u></b>				
Female	30	30.9	97.2	(65.6-138.7)	Female	10	10.6	94.7	(45.3-174.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	7.4	149.2	(74.4-267.0)	Male	13	9.7	133.7	(71.1-228.7)
Female	3	1.9	nc	(nc-nc)	Female	7	9.8	71.1	(28.5-146.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	92	93.3	98.6	(79.5-120.9)
Female	6	2.0	294.6	(107.6-641.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.5	107.1	(42.9-220.8)
Male	16	16.1	99.1	(56.6-161.0)	Female	3	3.9	nc	(nc-nc)
Female	14	9.3	150.7	(82.3-252.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	4.6	174.8	(75.3-344.5)
Male	10	4.3	230.3	(110.3-423.6)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	13	7.9	164.7	(87.6-281.7)
<b><u>Leukemia</u></b>					Female	31	24.5	126.4	(85.9-179.4)
Male	13	11.8	110.4	(58.7-188.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	8.6	58.1	(18.7-135.6)	Female	32	26.6	120.3	(82.2-169.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.9	101.0	(48.3-185.7)	Male	377	371.3	101.5	(91.5-112.3)
Female	1	3.2	nc	(nc-nc)	Female	392	397.7	98.6	(89.1-108.8)
<b><u>Lung and Bronchus</u></b>									
Male	43	49.0	87.7	(63.4-118.1)					
Female	38	52.9	71.8	(50.8-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;